Research programme: fibroblast growth factor receptor type 2/3 antagonists - Genosco
Alternative Names: FGFR2/3 inhibitors - GenoscoLatest Information Update: 29 Apr 2021
At a glance
- Originator Genosco
- Class Antineoplastics; Small molecules
- Mechanism of Action Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cholangiocarcinoma
Most Recent Events
- 05 Apr 2021 Early research in Cholangiocarcinoma in USA (unspecified route), prior to April 2022 (Genosco pipeline, April 2022)